Searching…
Grade 4 dermatological toxicities are rare, which present as severe rash and skin infection. Herein, we retrospectively reported the grade 4 dermatological toxicities of zanubrutinib in three consecutive …
In addition to the nonpalpable asymptomatic petechial rash thought to result from ibrutinib-induced platelet dysfunction, at least two other forms of skin manifestations of BTKi therapy have been …
Learn about the side effects of zanubrutinib, from common to rare, for consumers and healthcare professionals.
Dermatologic toxicities in patients receiving zanubrutinib have not been thoroughly characterized to date. Here, we present a case of a petechial ecchymotic reaction to zanubrutinib localized to a …
Some patients may experience a series of side effects after the treatment of zanubrutinib. Grade 4 dermatological toxicities are rare, which present as severe rash and skin infection.
Although zanubrutinib is associated with fewer off-target effects than first-generation BTKi, dermatologic toxicities may still occur. We report the case of an 81 year-old man with Waldenström’s …
Dermatologic toxicities in patients receiving zanubrutinib have not been thoroughly characterized to date. Here, we present a case of a petechial ecchymotic reaction to zanubrutinib localized to a …
Zanubrutinib is a next-generation Bruton tyrosine kinase (BTK) inhibitor. Cutaneous adverse events, and more specifically ecchymoses or bruises, have been widely described with BTK inhibitors. The …
Patients treated with BTK inhibitors frequently demonstrate dermatologic toxicities, such as bruising, rash, infections, mucosal symptoms, neutrophilic dermatoses, vasculitis, infections, nail plate …
Radiation recall dermatitis (RRD) is a drug-induced inflammatory skin reaction in a previously irradiated area of skin, triggered by administering certain systemic medications. 1 It can occur months to years …
